Effect of Remote Intervention in Patients With SCAD
WithdrawnNot applicableNCT04795492
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The study was a multicenter, two-arm, parallel, open-label, prospective clinical trial that evaluated a remote intervention with 1 year of follow-up.
Study details
- Official title
- Effect of Remote Intervention in Patients With SCAD
- Conditions
- Interventions
- Behavioral: remote intervention
- Behavioral: Routine outpatient follow-up
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
- Start date
- 2021-04-01
- Primary completion
- 2023-04
- Sex
- All
- Age range
- from 18 Years to 99 Years
- Results posted
- No results posted in this snapshot
- Countries
- China
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. Aged between 18-99 years 2. Diagnosed with SCAD according to guidelines by coronary CTA or coronary angiography (including stable angina, ischemic cardiomyopathy, and the stable course after acute coronary syndrome) 3. Have sufficient Chinese language proficiency to reading, speaking and listening 4. Live with at least one caregiver or guardian in the household 5. Presence of stable hemodynamics without using vasopressor 6. Able to individually consent 7. Not participating in any other clinical trial Exclusion Criteria: 1. Unable to provide informed consent 2. Unable to be involved in clinical follow-up and treatment 3. Suffered comorbidity with a life expectancy of less than 1 year 4. Have contra-indication to cardiac rehabilitation 5. Acute coronary syndrome 6. History of noncompliance with medical therapy 7. Severe valvular disease or valvular disease likely to require surgery or percutaneous valve replacement during the trial 8. Planned major surgery necessitating interruption of antiplatelet therapy 9. Inability to comply with the protocol 10. Has any condition that, in the opinion of the investigator, would make participation not be in the best interest of the subject or that could prevent, limit or confound the protocol-specified assessments
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04795492